[1] Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet, 2015, 386:1546-1555.
[2] Wang L, Wang B, You H, et al. Platelets' increase is associated with improvement of liver fibrosis in entecavir-treated chronic hepatitis B patients with significant liver fibrosis. Hepatol Int, 2018,12:237-243.
[3] Jeon HJ, Jung SW, Park NH, et al. Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir. Clin Mol Hepatol, 2017, 23:230-238.
[4] Yim HJ, Kim IH, Suh SJ, et al. Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: a randomized controlled trial. J Viral Hepat, 2018, 59:489-494.
[5] Shi H,Li XY,Zhu JY,et al. Clinical effect of entecavir versus tenofovir in treatment of HBe Ag-positive chronic hepatitis B patients with a high viral load:a comparative analysis. Zhonghua Gan Zang Bing Za Zhi, 2017, 25:721-725.
[6] Papatheodoridis GV, Sypsa V, Dalekos G, et al. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapyis similar to the general population. J Hepatol, 2018, 68:1129-1136.
[7] Chen N, Zhang J, Zhang Q, et al. Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series. BMC Pharmacol Toxicol, 2018, 19:23.
[8] Shang J, Wen Q, Wang CC, et al. Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: Long-term follow-up. J Viral Hepat, 2017, 24:43-48.
[9] Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol, 2018, 68:672-681.
[10] Chan HL, Fung S, Seto WK, et al. Improved bone and renal safety of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF): preliminary results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B (CHB). J Hepatol,2017,66:1-32.
[11] Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol, 2016, 1:196-206.
[12] Liu S, Zheng H, Huang Y, et al. The effect of peginterferon alpha-2a vs. interferon alpha-2a on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients. Clin Res Hepatol Gastroenterol, 2015, 40:304-308.
[13] Li SY, Li H, Xiong YL, et al. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study. J Viral Hepat, 2017, 24:12-20.
[14] Luker J, Gniewek T, Johnson C. Combination of pegylated interferon and nucleos(t)ide therapy: toward a cure of hepatitis B virus infection? Gut Liver, 2016, 10:497-498.
[15] Chung-Il W, Ray KW, Jr GJB, et al. Potential efficacy of pegylated interferon-α and a nucleos(t)ide analogue as combination therapy for HBeAg-positive chronic hepatitis B. Gut Liver, 2016, 10:611-616.
[16] Phyo WW, Soh AYS, Seng GL, et al. Search for a cure for chronic hepatitis B infection: How close are we? World J Hepatol, 2015, 7:1272-1281.
[17] Soriano V. Hot news: hepatitis B gene therapy coming to age. AIDS Rev, 2018, 20:125-127.
[18] Flisiak R, Jaroszewicz J, Lucejko M.siRNA drug development against hepatitis B virus infection. Expert Opin Biol Ther,2018,18:609-617.
[19] Yuen MF, Kim DJ, Weilert F, et al. NVR 3-778, a first-in-class HBV core inhibitor, alone and in combination with Peg-Interferon (PegIFN), in treatment-naive HBeAg-positive patients: early reductions in HBV DNA and HBeAg. J Hepatol, 2016, 64:10-11.
[20] Mani N, Cole AG, Phelps JR, et al. Preclinical profile of AB-423, an inhibitor of Hepatitis B virus pgRNA encapsidation. Antimicrob Agents Chemother, 2018,62.
[21] Mamun AM, Michel B, Andrew V. Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive bangladeshi patients with HBeAg+chronic hepatitis B infection. PLoS One, 2016, 11:e0156667.
[22] Noordeen F, Scougall CA, Grosse A, et al. Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection. PLoS One, 2015, 10:e0140909.
[23] Roehl I, Seiffert S, Brikh C, et al. Nucleic acid polymers with accelerated plasma and tissue clearance for chronic hepatitis B therapy. Mol Ther Nucleic Acids, 2017, 8:1-12.
[24] Quinet J, Jamard C, Burtin M, et al. Nucleic acid polymer REP 2139 and nucleos(t)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks. Hepatology, 2018, 67:2127-2140.
[25] Chen J, Zhang W, Lin J, et al. An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. Mol Ther, 2014, 22:303-311.
[26] Martin P, Dubois C, Jacquier E, et al. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut, 2015, 64:1961-1971.
[27] Huang D, Sansas B, Jiang JH, et al. Recognition of core- and polymerase-derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients. J Viral Hepat, 2017, 24:66-74.
[28] Dembek C, Protzer U, Roggendorf M.Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination. Curr Opin Virol, 2018, 30:58-67. |
